Theravance Biopharma Told Investors R&D Costs Were Declining Following Completion of CYPRESS Enrollment

NEW YORK , March 11, 2026 /PRNewswire/ -- Theravance Biopharma (NASDAQ: TBPH) shareholders lost approximately 26% of their investment on March 3, 2026, when the Company disclosed that its Phase 3 CYPRESS trial failed. Shareholders who lost money are encouraged to submit their information now. You may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500.

Theravance reported $22 million in operating expenses while the CYPRESS trial was still enrolling, highlighting substantial cash burn on a single high-risk program. Although the company framed R&D costs as declining post-enrollment, the spending underscores the company's financial dependence on a trial that ultimately failed.

TBPH investors who suffered a loss are encouraged to get more information about this investigation. You may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500.

Levi & Korsinsky, LLP -- Top 50 securities litigation firm (ISS, seven consecutive years). Over 70 professionals. Hundreds of millions recovered.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171

View original content to download multimedia:https://www.prnewswire.com/news-releases/tbph-reported-22m-in-operating-expenses-while-advancing-trial-enrollment----levi--korsinsky-llp-investigates-302710583.html

SOURCE Levi & Korsinsky, LLP